17α-Acyloxy-5β-pregnanes (I) and 17α-acyloxy-5α-pregnanes (IV) have an excellent activity split providing high topical anti-inflammatory activity with very low systemic side effects.

Patent
   4444689
Priority
Jan 31 1980
Filed
Sep 03 1981
Issued
Apr 24 1984
Expiry
Apr 24 2001
Assg.orig
Entity
Large
14
1
EXPIRED
1. A 5β-steroid of the formula ##STR1## where R2 is a hydrogen, fluorine or chlorine atom or methyl group;
R6 is a hydrogen, fluorine or chlorine atom or methyl group;
R7 is a hydrogen, fluorine or chlorine atom;
R9 is a hydrogen, fluorine or chlorine atom;
R11 is a chlorine or oxygen atom or hydroxyl group; when R11 is a chlorine atom or hydroxyl group the between R11 and C11 is a single bond in the β configuration and when R11 is an oxygen atom the between R11 and C11 is a double bond;
R16α is a hydrogen, fluorine or chlorine atom or methyl group;
R16β is a hydrogen atom or methyl group with the proviso that one of R16α or R16β is a hydrogen atom;
R17 is alkyl of 1 through 6 carbon atoms, phenyl, p-methylphenyl, p-carboxyphenyl or p-carboalkoxyphenyl;
R21 is a hydrogen, fluorine, chlorine or bromine atom or a --OR21α or --OSO2 CH3 group;
R21α is a hydrogen atom, --COR21β or --PO(OH)2 and pharmaceutically acceptable salts thereof;
R21β is alkyl of 1 through 6 carbon atoms, phenyl, p-methylphenyl, or p-carboxyphenyl, p-carboalkoxyphenyl, --CH2 CH2 COOH and pharmaceutically acceptable salts thereof;
is a single or double bond; and
indicates the attached group can be in either the α or β configuration.
2. A compound according to claim 1 where R2 is a hydrogen atom or methyl group.
3. A compound according to claim 2 where R2 is a hydrogen atom.
4. A compound according to claim 1 where R6 is a hydrogen or fluorine atom or methyl group.
5. A compound according to claim 4 where R6 is a hydrogen atom.
6. A compound according to claim 1 where R7 is a hydrogen or chlorine atom.
7. A compound according to claim 6 where R7 is a hydrogen atom.
8. A compound according to claim 1 where R16α is a hydrogen atom or methyl group.
9. A compound according to claim 1 where R16β is a hydrogen atom or methyl group.
10. A compound according to claim 9 where R16β is a methyl group.
11. A compound according to claim 1 where R17 is alkyl of 1 thru 5 carbon atoms, phenyl, or paramethylphenyl.
12. A compound according to claim 11 where R17 is alkyl of 1 thru 4 carbon atoms or phenyl.
13. A compound according to claim 1 where R21 is a hydrogen, fluorine, or chlorine atom or a --OR2group where R21α is defined in the specification.
14. A compound according to claim 13 where R21 is a hydrogen or chlorine atom or --OR2group where R21α is --COR21β where R21β is defined in the specification.
15. A compound according to claim 1 which is 21-chloro-9α-fluoro-11β,17α-dihydroxy-16β-methyl-5.b eta.-pregnane-3,20-dione 17-propionate.

This is a division of application Ser. No. 117,401, filed Jan. 31, 1980 now U.S. Pat. No. 4,318,853.

The present invention relates to 5α and 5β- 17α-acyloxy corticoids which are useful as topical anti-inflammatory agents for which the essential material constituting a disclosure thereof is incorporated by reference here from U.S. patent application Ser. No. 117,401, filed Jan. 31, 1980, now U.S. Pat. No. 4,318,853.

Ayer, Donald E., Schlagel, Carl A.

Patent Priority Assignee Title
10000525, Apr 05 2010 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
10206933, May 28 2008 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of NF-kB for treatment of disease
10799514, Jun 29 2015 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
10857161, May 28 2008 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of NF-kB for treatment of disease
11382922, Mar 07 2019 ReveraGen BioPharma, Inc. Aqueous oral pharmaceutical suspension compositions
11471471, Mar 07 2019 ReveraGen BioPharma, Inc. Aqueous oral pharmaceutical suspension compositions
11690853, Jun 29 2015 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of NF-κβ for treatment of disease
11833159, May 28 2008 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of NF-kB for treatment of disease
8207151, May 28 2008 Reveragen Biopharma, Inc Non-hormonal steroid modulators of NF-κB for treatment of disease
8334279, Jul 20 2010 Validus Genetics Non-hormonal steroid modulators of NF-κB for treatment of disease
8673887, May 28 2008 Reveragen Biopharma, Inc Non-hormonal steroid modulators of NF-kB for treatment of disease
9198921, Apr 05 2010 FREERUN TECHNOLOGIES, INC Non-hormonal steroid modulators of NF-κB for treatment of disease
9434758, May 28 2008 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
9649320, May 28 2008 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
Patent Priority Assignee Title
4336200, Jan 31 1980 UPJOHN COMPANY THE, A CORP OF DE 17α-Acyloxy-5β-corticoids
/
Executed onAssignorAssigneeConveyanceFrameReelDoc
Sep 03 1981The Upjohn Company(assignment on the face of the patent)
Date Maintenance Fee Events
Apr 27 1987M170: Payment of Maintenance Fee, 4th Year, PL 96-517.
Apr 29 1987ASPN: Payor Number Assigned.
Apr 26 1992EXP: Patent Expired for Failure to Pay Maintenance Fees.


Date Maintenance Schedule
Apr 24 19874 years fee payment window open
Oct 24 19876 months grace period start (w surcharge)
Apr 24 1988patent expiry (for year 4)
Apr 24 19902 years to revive unintentionally abandoned end. (for year 4)
Apr 24 19918 years fee payment window open
Oct 24 19916 months grace period start (w surcharge)
Apr 24 1992patent expiry (for year 8)
Apr 24 19942 years to revive unintentionally abandoned end. (for year 8)
Apr 24 199512 years fee payment window open
Oct 24 19956 months grace period start (w surcharge)
Apr 24 1996patent expiry (for year 12)
Apr 24 19982 years to revive unintentionally abandoned end. (for year 12)